GMND yields 1000000.00% · ABBV yields 3.06%● Live data
📍 GMND pulled ahead of the other in Year 1
Combined, GMND + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GMND + ABBV for your $10,000?
Green Mountain Development Corp provides project development services for capital providers and technology operators; and distributes licensed products related to the energy, agricultural, and environmental sectors. The company assists clients with preliminary development work, including project due diligence, investor presentations, identification of project capital sources and technology vendors, and negotiation of a joint venture agreement between investors and the client. It also distributes Bio-Miracle microbial blends that are used for agricultural growth enhancement, composting acceleration, pond and lake water treatment, hydrocarbon reduction in soil and water, and animal and green waste treatment. The Bio-Miracle product lines include Remediline remediation products comprising SPILL KILL PRO, an oil spill cleanup product for soil and tank applications, and SIZZLE CLEAN, a microbe water based fizzing tablet for parts cleaning applications; Wasteline waste management products consisting of MANURE KING for cow/horse/pig manure control and SPARKLE CLEAN for septic and cesspool cleanup; and Bi-Agra agricultural products for increased plant health, size, and yield improvement, such as Bi-Agra-100, Bi-Agra-200, TOO TALL TOMATOES, and COMPOST PAL for backyard and commercial composting acceleration, as well as non-invasive dethatch applications. In addition, it focuses on the research, development, and production of a range of life science products. The company is based in Carlsbad, California.
Full GMND Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.